Importantly, many targeting-type 2-cytokine therapies (for example, IL-4, IL-13, IL-5, IL-31 inhibitors and anti-IgE monoclonal antibodies) currently have shown benefits in AD patients [25, 26]. The gene discussed is IL31; the disease is Alzheimer disease.